Document:

Exhibit
                                        10.56

April 30, 2020

 

Dear Mr. Sheikh,

Bioxytran, Inc. (together with any affiliates, the "Company") is pleased to confirm its offer to employ as Executive Vice President of Business Development reporting to the Board of Directors.  As discussed, your official start date with the Company was effective April 30, 2020.

 

This position will be unpaid until a later date determined by the Board of Directors. You also will be entitled to three weeks of paid vacation that begins accruing on a monthly basis from your first day of employment.

 

Upon the fulfillment of any eligibility requirements, you will be eligible to participate in the employee benefit plans that the Company may offer to its employees. Descriptions of the benefit plans currently being offered, if any, have been delivered to you. Any Company benefit plan may, from time to time, be amended or terminated by Company in its sole discretion with or without prior notice.

 

This employment offer is contingent upon the conditions outlined below. Please understand the resulting formality of this offer letter.

 

1)      As a condition of employment (or continuing employment) with the Company, you are required to execute the enclosed CONFIDENTIALITY AND DEVELOPMENTS AGREEMENT ("Agreement"). This is an important legal document that restricts certain activities during your employment and for a period of time after you leave the Company. You should carefully read the entire document, review its provisions with your counsel and advisors, and decide whether or not to enter into this Agreement. You must sign and return the Agreement to me no later than one week prior to your start date.

 

2)    Your employment (or continued employment) by the Company is based in part on your acceptance and agreement not to compete with the Company. Specifically, you agree that for a period of twelve (12) months from the date of termination of your employment or cessation of your business relationship with the Company you will not, either alone or in conjunction with any person or entity, directly, or indirectly (a) cause or attempt to cause any client, customer, distributor, partner, joint venturer or supplier of the Company or any of the Company’s affiliates to terminate or materially reduce its business with the Company or any such affiliate or (b) participate, accept employment or engage in (other than through the ownership of two percent (2%) or less of any class of securities registered under the Securities Act), or otherwise lend assistance (financial or otherwise) to any person or entity participating or engaged in any line of business in which the Company is participating or engaged on the date hereof anywhere in the world.

 

3)    In making this offer of employment (or in agreeing to continue your employment), the Company is relying upon your representation that you are not under any obligation to any former employer or any person, firm, or corporation that would prevent, limit, or impair in any way the performance by you of your duties as an employee of the Company.

 

4)    The Immigration Reform and Control Act requires employers to verify the employment eligibility and identity of new employees. Enclosed is a copy of the Form 1-9 that you will be required to complete. Please bring this form and appropriate documents listed on the form with you on the first day you report for work.

 

5)    You may be required to undergo a background check, including a criminal background check, at any time during your employment, and your employment is contingent upon results satisfactory to the Company.

 

6)    Your employment with the Company is an at-will employment relationship. This means that your employment is not guaranteed for any specified period of time and you or the Company may terminate the relationship at any time, with or without notice or cause. The Company simply asks that you provide reasonable notice of your departure.

 

7)    You are the record and beneficial owner of eight million eight hundred thousand (8,800,000) shares of the Common Stock of the Company, vesting over 3 years in four equal portions on the anniversary of this contract with the first portion at the signature of this agreement. In case of change in company control, the shares will vest immediately. You acknowledge and agree that (a) the Company intends to file a registration statement on Form S-1 or other appropriate form with the SEC in order to register shares of the Company’s common stock for sale and distribution, and (b) you agree that you will not directly or indirectly, nor direct any person acting on behalf of or pursuant to any understanding with you, execute any purchases or sales, including, without limitation, short sales, of any securities of the Company during the period commencing on the date the Company files a registration statement with the SEC and ending 180 days after the effective date of such registration statement.

 

    52

     

    

 

8)    If your employment relationship with the Company is terminated without cause prior to April 30, 2023, then the Company shall pay you a lump sum of $100,000 in severance, such payment to be conditioned upon your execution and delivery of a general release and covenant not to sue the Company containing standard or “market” terms; provided.

 

If there is anything about the offer of employment that was verbally made to you but is not mentioned in this letter, please contact me as soon as possible to discuss it. Otherwise, it will be understood that this letter fully encompasses all aspects of our offer of employment to you and supersedes all prior offers, both verbal and written.

 

Please indicate your acceptance of this Agreement by signing and dating the enclosed copies of this letter and the Agreement, and returning them in the enclosed envelope.

 

We are pleased that
you will be working with us. Please do not hesitate to call me if you have any questions.

 

	
BIOXYTRAN, INC.

	
 

	 	 
	
 

	
 

	
By: David Platt, CEO

	
 

 

	
Agreed & Accepted:

	
 

	 	 
	
 

	
 

	
Mike Sheikh

	
 

 

    53Exhibit
                                        10.57

 

	
Issuer:

	
Bioxytran Inc. or SPV as designated (the “Company”)

	
 

	
 

	
Investors:

	
Black Diamond Financial Group LLC (“Black Diamond” or “BDFG”), and/or its assigns as designated by BDFG, (collectively, the “Investor” and, together with permitted assignees, the “Holders”).

 

Investment: The terms set forth below are indicative only and subject to review and acceptance of the Company and the Investor.

 

	
Joint Venture:

	
The parties agree to form a joint venture, formed as a subsidiary to Bioxytran, for the development, distribution of prolectin-1 and prolactin-1i. The joint venture shall by the end of below funding be owned 50%-50% between the Company and the Investor and controlled on a 50%-50% basis.

	
 

	
 

	
Contributions by Company:

	
The Company shall assign the exclusive use of prolectin-1and prolactin-1i for the treatment of Coronavirus and Influenza to the joint venture. This shall include an exclusive, non-revocable license for provisional or obtained patents for the indication. The Company will also contribute the expertise and knowledge to validate products for distribution based on indications of use of prolectin-1 and prolactin-1i.

	
 

	
 

	
Contributions by Investor:

	
The Investor shall contribute capital for validation as per the agreed budget and shall be responsible for developing and implementing the necessary financial structures for distributions of drugs based on prolectin-1 and prolactin-1i. 

	
 

	
 

	
Project Supervision:

	
The therapeutic development of prolectin-1 and prolactin-1i will be managed by the Company.

	
 

	
 

	
Budget of JV:

	
The Investor will fund the joint venture on the following budget:

	
 

	
•

	
Preparatory Period – Two Weeks - $50,000 

	
 

	
○

	
To be advance within five days of signing, funds to be used for the filing of intellectual property and hiring of Project Manager and filing of initial Pre-IND.                                                                                 

	
 

	
•

	
Stage One – Four to Six Weeks- $1.4M

	
 

	
○

	
Funding to be initiated 20 days after signing and advanced on a budgeted/approved basis.  

	
 

	
○

	
Use of funds for manufacturing of drug, auditing, and testing, and invitro testing

	
 

	
○

	
Milestones:  Invitro results, ie knowing it works, GMP product, and pre-IND submission, “go or no go” decision.

	
 

	
○

	
Issuance of 1.4 million 6-month warrants with an exercise price of $2.00 in BIXT

 

	
 

	
•

	
Stage Two - Four to Six Weeks - $1.0M

	
 

	
○

	
Funding to be advance on a budgeted/approved basis upon completion of Stage One

	
 

	
○

	
Respond to feedback and protocols from IND.

	
 

	
○

	
Animal Studies and invitro studies as recommended by IND.

	
 

	
○

	
Sites selection for human trials.

	
 

	
○

	
Nuclear Magnetic Residence testing

	
 

	
○

	
Milestones: Drug is binding to site, “go or no go” decision

	
 

	
○

	
Issuance of 1.0 million 2-year warrants with an exercise price of $2.50 in BIXT

 

	
 

	
•

	
Stage Three – Four to Six Weeks - $2.6M

	
 

	
○

	
Funding to be advanced on a budgeted/approved basis commencing at the end of Stage Two

	
 

	
○

	
Clinical trial for forty patients at an estimated cost of $65,000 per patient

	
 

	
○

	
Success!

	
 

	
○

	
Issuance of 2.6 million 3-year warrants with an exercise price of $3.00 in BIXT

 

    54

     

    

 

 

	
“No Go” Decision:

	
Should a “no go” decision be reached at the end of any stage indicating the failure of prolectin-1 and prolactin-1i for COVID 19 and Influenza, the joint venture partners will receive the license of prolactin-1c for Cancer Metastasis and develop a budget for funding the indication and seek to raise capital for these indications, being mutually diluted by such capital.

	
 

	
 

	
Conversion option:

	
After complete
funding of the $5.0M, but before signature of a licensing deal. BDFG can convert its 50% ownership in the JV into a 17.5%
owner-stake of BIXT. (The certificate(s)
shall be free of restrictive legends and trading restrictions if the shares of Common Stock underlying the portion of the
conversion right being converted are eligible under a resale exemption pursuant to Rule 144(b)(1)(ii) and Rule 144(d)(1)(ii)
of the Securities Act of 1933, as amended).

	
 

	
 

	
Funding Earn In:

	
For each $50,000 advanced under this contract, the Investor will earn a 0.5% interest in the JV and its respective terms. 

	
 

	
 

	
Conditions:

	
The transactions contemplated hereby will be subject to customary closing conditions, including, but not limited to:

 

- Satisfactory results of business, tax, legal, environmental and regulatory due diligence, as determined by BDFG in its sole discretion;

- The parties agreeing upon and executing and delivering the Definitive Agreements;

- Notes on terms satisfactory to the parties;

- Receipt of any required governmental and third-party consents;

- Absence of injunction, litigation, etc.;

- No material adverse change;

- The shares to be issued pursuant to the conversion of the Notes and exercise of the Warrants will be authorized and reserved for issuance, subject to repayment of the existing convertible Notes.

 

	
Confidentiality:

	
This Term Sheet is confidential, and none of its provisions or terms shall be disclosed to anyone who is not a prospective purchaser of the securities contemplated herein, an officer or director of the Company or such party’s respective agents, advisers or legal counsel, unless required by law.  BDFG shall continue to be under the confidentiality obligations set forth in the Confidentiality Agreement entered into with the Company on March 29, 2020.

	
 

	
 

	
Definitive Agreements:

	
Mutually acceptable definitive agreements will be initially prepared by Black Diamond’s counsel, which will include agreements covering the above items described in this term sheet and such other terms as may be mutually acceptable to the parties thereto (the “Definitive Agreements”).  The Definitive Agreements will contain other customary and appropriate terms in addition to the terms set forth herein and agreed upon by the parties.

	
 

	
 

	
Governing Law:

	
State of Colorado.

	
 

	
 

	
Due Diligence:

	
This term sheet is subject to the satisfactory completion of due diligence by the Investor and its affiliates.  Black Diamond and its representatives will be provided reasonable access at reasonable times to the books, records, financial statements, contracts, internal financial reports and projections, other materials and assets, as well as key personnel, as reasonably requested to allow the Investor and its affiliates to adequately complete their due diligence examination. The Company’s representatives will cooperate with Black Diamond and its affiliates and representatives in connection with their due diligence investigation.

	
 

	
 

	
Costs and Expenses:

	
The Company shall promptly reimburse Black Diamond for all reasonable out of pocket fees, costs and expenses incurred by Black Diamond relating to the transactions described herein to fund the investment, including expenses related to the due diligence investigation as well as the preparation and negotiation of the agreements and other documentation related to the issuance and sale of the Parts, which shall not exceed $25,000.  Such expenses to be reimbursed only if the Closing occurs and such amounts being paid to Black Diamond at the Closing.

	
 

	
 

	
Transaction Fee:

	
BDFG, or its assigns shall be entitled to a Structuring and Management Fee of $200,000 to be paid by the JV on a prorated basis as funds are advanced at each stage for the first $4,000,000 adv to the JV. 

    55

     

    

 

	
 

	
BDFG and the Company will agree to payment of any other Finders or engagement of Investment Bankers, if funding above and beyond initial budget will be required.

	 	 

	
Exclusivity:

	
Upon the acceptance of this agreement Black Diamond, on behalf of itself and the funds it manages, shall have the Exclusive right to fund the investments under the terms provided by this term sheet.  Such exclusivity shall continue as long as Black Diamond maintains the budgeted advances as set forth.  The Company shall not directly or indirectly solicit, encourage, initiate or provide any information to any person, entity or group concerning the Transaction or matters described herein that would conflict with, or preclude, consummation of the transaction contemplated in this term sheet. The exclusivity is released if parties do not sign definitive documents within 15 days and is contingent upon an immediate non-refundable payment of the $50,000 for the preparatory period.

 

	
General:

 

	
1)

	
The Company can issue a press release or other public announcement regarding this transaction (including a Form 8-K), provided that the Company shall provide Black Diamond 2 days prior written notice and opportunity to review and provide reasonable comments to such press release and Form 8-K, provided however, such review and right to comment of Black Diamond’s shall not prevent the Company from proceeding with any such filing in order to complying with its filing and disclosure obligations under applicable law.

 

This Term Sheet reflects the principal terms of the transactions contemplated hereby.  Notwithstanding any prior corporate approvals of this Term Sheet or any other action, no party or any of its affiliated companies, or the officers, directors or agents of any of them will have any legal obligation (except the obligation to negotiate in good faith and finalize the definitive agreements, subject only to the specific contingencies and including all of the transaction terms described in this Term Sheet) to any other party or any other person or entity by reason of this Term Sheet or any other matter contemplated hereby or giving rise hereto, until the parties execute definitive agreements providing for the transactions contemplated hereby; provided that the terms under section titled Confidentiality and Exclusivity shall be binding on the parties.

 

	
ACCEPTED AND AGREED TO BY

	 
	
BLACK DIAMOND FINANCIAL GROUP LLC

 

	
 

	
 

	
By: Patrick Imeson

	
 

	
Title:  Managing Director

	
 

	 	 

	
BIOXYTRAN, INC.

	
 

	
 

	
 

	
 

	
 

	
By:  David Platt

	
 

	
Title: Chairman and Chief Executive Officer

	
 

 

 

    56

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]